loading page

Effects of androgen deprivation therapy on cognitive functions in patients with metastatic prostate cancer: A multicentric, prospective study of the Society of Urological Surgery Andrology group
  • +9
  • Onder Cinar,
  • Tahsin Turunc,
  • Ilke Onur Kazaz,
  • Omer Yildirim,
  • Hasan Deliktas,
  • Ahmet Cihan,
  • Ahmet Gudeloglu,
  • iyimser üre,
  • Serkan Deveci,
  • Bahadir Sahin,
  • Bilge Cinar,
  • Hamdi Ozkara
Onder Cinar
Zonguldak Bülent Ecevit University
Author Profile
Tahsin Turunc
Iskenderun Gelisim Hospital
Author Profile
Ilke Onur Kazaz
Karadeniz Technical University
Author Profile
Omer Yildirim
Istanbul University Cerrahpasa Faculty of Medicine
Author Profile
Hasan Deliktas
Mugla Sitki Kocman University
Author Profile
Ahmet Cihan
Author Profile
Ahmet Gudeloglu
Author Profile
iyimser üre
Eskişehir Osmangazi Üniversitesi Tıp Fakültesi
Author Profile
Serkan Deveci
Istanbul Rumeli University
Author Profile
Bahadir Sahin
Marmara Universitesi Tip Fakultesi
Author Profile
Bilge Cinar
Zonguldak Bülent Ecevit University
Author Profile
Hamdi Ozkara
Istanbul University Cerrahpasa Faculty of Medicine
Author Profile

Abstract

Abstract Aims of the study: The aim of this study was to investigate the impact of testosterone deficiency on cognitive functions in metastatic prostate cancer patients receiving androgen deprivation therapy (ADT). Methods: In this multicentric prospective study, 65 metastatic prostate cancer patients were evaluated. Demographic and clinical data were recorded. Cognitive functions were assessed using the Symbol Digit Modalities Test, the California Verbal Learning Test Second Edition, the Brief Visuospatial Memory Test - Revised, and the Trail Making Test. Depressive symptoms were assessed using the Beck Depression Inventory. Cognitive functions and depressive symptoms were recorded before the androgen deprivation therapy and at the 3- and 6-month follow ups. Results: At the basal cognitive assessment, the mean Symbol Digit Modalities Test, the California Verbal Learning Test Second Edition, the Brief Visuospatial Memory Test - Revised scores were 25.84 ± 17.54, 32.68 ± 10.60, and 17.63 ± 11.23, respectively, and the mean time for the Trail Making Test was 221.56 ± 92.44 s., and were similar at the 3-month, and 6-month controls (p > 0.05). The mean pretreatment, third and sixth month testosterone levels were 381.40 ± 157.53 ng/dL, 21.61 ± 9.09 ng/dL, and 12.25 ± 6.45 ng/dL (p < 0.05), and the total PSA levels were 46.46 ± 37.83 ng/mL, 1.41 ± 3.31 ng/mL, and 0.08 ± 0.14 ng/mL (p < 0.05), respectively. Conclusion: The ADT in patients with metastatic prostate cancer does not affect patients’ cognitive functions and depressive symptoms. However, further prospective randomized studies with higher cohorts and longer follow up periods are needed.

Peer review status:ACCEPTED

02 Dec 2020Submitted to International Journal of Clinical Practice
03 Dec 2020Submission Checks Completed
03 Dec 2020Assigned to Editor
03 Dec 2020Reviewer(s) Assigned
06 Dec 2020Review(s) Completed, Editorial Evaluation Pending
12 Dec 20201st Revision Received
14 Dec 2020Submission Checks Completed
14 Dec 2020Assigned to Editor
14 Dec 2020Reviewer(s) Assigned
21 Dec 2020Review(s) Completed, Editorial Evaluation Pending
18 Feb 2021Editorial Decision: Accept